
Nader Yatim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/155980/publications.pdf Version: 2024-02-01



NADER YATIM

| # | Article | lF | CITATIONS |
|----|---|------|-----------|
| 1 | Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. Journal of Allergy and Clinical Immunology, 2022, 149, 550-556.e2. | 2.9 | 25 |
| 2 | Persistent bilateral Tapia syndrome following critical COVID-19. Clinical Neurophysiology, 2021, 132, 505-506. | 1.5 | 7 |
| 3 | Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients. Scientific Reports, 2021, 11, 11886. | 3.3 | 35 |
| 4 | Platelet activation in critically ill COVID-19 patients. Annals of Intensive Care, 2021, 11, 113. | 4.6 | 61 |
| 5 | Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Science Advances, 2021, 7, . | 10.3 | 27 |
| 6 | Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nature Immunology, 2021, 22, 1428-1439. | 14.5 | 110 |
| 7 | Lupus Anticoagulant Single Positivity During the Acute Phase of COVIDâ€19 Is Not Associated With Venous Thromboembolism or Inâ€Hospital Mortality. Arthritis and Rheumatology, 2021, 73, 1976-1985. | 5.6 | 21 |
| 8 | Analysis of Tâ€cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblainâ€like lesions during the COVIDâ€19 pandemic. British Journal of Dermatology, 2021, 185, 1242-1244. | 1.5 | 5 |
| 9 | Type I interferon response and vascular alteration in chilblainâ€like lesions during the COVIDâ€19 outbreak*. British Journal of Dermatology, 2021, 185, 1176-1185. | 1.5 | 33 |
| 10 | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020, 369, 718-724. | 12.6 | 2,374 |
| 11 | Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis, 2020, 23, 611-620. | 7.2 | 204 |
| 12 | RIPK3 Activation Leads to Cytokine Synthesis that Continues after Loss of Cell Membrane Integrity. Cell Reports, 2019, 28, 2275-2287.e5. | 6.4 | 85 |
| 13 | Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. Revue De Medecine Interne, 2018, 39, 130-133. | 1.0 | 32 |
| 14 | Autophagy diminishes the early interferon-Î ² response to influenza A virus resulting in differential expression of interferon-stimulated genes. Cell Death and Disease, 2018, 9, 539. | 6.3 | 21 |
| 15 | Dying cells actively regulate adaptive immune responses. Nature Reviews Immunology, 2017, 17, 262-275. | 22.7 | 303 |
| 16 | Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. Journal of Experimental Medicine, 2017, 214, 2231-2241. | 8.5 | 100 |
| 17 | Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspaseÂdeficiency. Nature Cell Biology, 2017, 19, 1116-1129. | 10.3 | 181 |
| 18 | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nature Immunology, 2015, 16, 850-858. | 14.5 | 244 |

NADER YATIM

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 19 | RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8 ⁺ T cells. Science, 2015, 350, 328-334. | 12.6 | 466 |
| 20 | RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis. Cell Death and Differentiation, 2014, 21, 1511-1521. | 11.2 | 242 |
| 21 | Widespread Mitochondrial Depletion via Mitophagy Does Not Compromise Necroptosis. Cell Reports, 2013, 5, 878-885. | 6.4 | 240 |
| 22 | Dying to Replicate: The Orchestration of the Viral Life Cycle, Cell Death Pathways, and Immunity. Immunity, 2011, 35, 478-490. | 14.3 | 56 |